Turnstone BiologicsTSBX
TSBX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 [Q3] → 28 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
1.5% less ownership
Funds ownership: 49.47% [Q3] → 47.97% (-1.5%) [Q4]
14% less capital invested
Capital invested by funds: $6.37M [Q3] → $5.51M (-$864K) [Q4]
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for TSBX.
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting.
Positive
Zacks Investment Research
1 month ago
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
4 months ago
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.
Neutral
Benzinga
7 months ago
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.
Negative
InvestorPlace
7 months ago
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents.
Neutral
GlobeNewsWire
7 months ago
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.
Neutral
GlobeNewsWire
7 months ago
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01.
Positive
24/7 Wall Street
7 months ago
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
Neutral
GlobeNewsWire
10 months ago
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A.
Neutral
GlobeNewsWire
10 months ago
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.
Charts implemented using Lightweight Charts™